Please login to the form below

Not currently logged in
Email:
Password:

Akcea Therapeutics

This page shows the latest Akcea Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Safety issues dampen enthusiasm for Akcea's volanesorsen

Safety issues dampen enthusiasm for Akcea's volanesorsen

Akcea Therapeutics says it plans to file for approval of its drug for rare disease familial chylomicronaemia syndrome (FCS) later this year on the back of positive clinical results – despite the ... Three patients developed serious (Grade 4)

Latest news

  • Amgen takes aim at cardio diseases with Arrowhead RNAi deal Amgen takes aim at cardio diseases with Arrowhead RNAi deal

    Amgen has bolstered its cardiovascular pipeline by licensing two gene silencing therapies developed by Arrowhead Therapeutics in a deal valued at up to $670m. ... Most notably, Ionis subsidiary Akcea Therapeutics is developing IONIS-APO(a) Rx, an

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics